Lederle vaccine pricing policy
Executive Summary
Company pledges no price increases for vaccine products in 1993 and commits to keeping 1994 price increase for individual vaccine products under the Consumer Price Index. The company says March 24 that annual price increases for all Lederle pharmaceutical products have averaged 1.5% over the last six years compared to the 4.2% annual inflation rate. The private sector price of the polio vaccine Orimmune increased from $9.37 to $9.89 between 1991 and 1992, while the government price increased by 9[cents] to $1.55. Meanwhile the price of the firm's DTP vaccine Tri-Immunol stayed the same for the private sector and decreased from $1.30 to 64[cents] to the government.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth